© Archyde.com/Dado Ruvic
Photographic illustration with several vials of vaccine once morest COVID-19 and a syringe in front of the Johnson & Johnson logo.
Jan 25 (Archyde.com) – Johnson & Johnson on Tuesday estimated revenue of between $3 billion and $3.5 billion from its COVID-19 vaccine this year, up from the $2.39 billion it generated in 2021, despite the manufacturer of medicines faces manufacturing problems and uneven demand.
J&J’s single-dose injection, once touted as an important tool for vaccinating people living in hard-to-reach areas, has fallen behind in its delivery schedule in the United States and Europe.
The drugmaker faced quality problems at a Baltimore manufacturing plant last year, resulting in the disposal of millions of doses.
The forecast comes at a time when the company is looking to separate its consumer health unit and focus on its medical device and pharmaceutical businesses.
(Reporting by Manas Mishra in Bangalore; edited in Spanish by Marion Giraldo)
